Ampio reports positive results in DME patients treated with Optina

Ampio Pharmaceuticals reported positive results in the phase 3 OptimEyes trial in patients with diabetic macular edema, according to a press release. The multiple site, randomized, placebo-controlled, parallel, double-masked study evaluated the safety and efficacy of two doses of Optina (danazol) in adult patients with DME. Dosage was based on patient’s body mass index, the release said.